

Product Monograph
Including Patient Medication Information

 **WELIREG®**

belzutifan tablets

For oral use

40 mg belzutifan

Antineoplastic agent

Merck Canada Inc.
16750 route Transcanadienne
Kirkland QC Canada H9H 4M7
www.merck.ca

Date of Authorization:
2026-08-05

Control Number: 501771

Recent Major Label Changes

1 Indications	12/2024
1 Indications, 1.2 Geriatrics	12/2024
4 Dosage and Administration, 4.2 Recommended Dose and Dosage Adjustment (Geriatrics)	12/2024
4 Dosage and Administration, 4.2 Recommended Dose and Dosage Adjustment (Renal Insufficiency, Hepatic Insufficiency)	08/2026
7 Warnings and Precautions, General (Anemia, Hypoxia)	12/2024
7 Warnings and Precautions, 7.1.4 Geriatrics	12/2024
7 Warnings and Precautions, 7.1.5 Dual UGT2B17 and CYP2C19 Poor Metabolizers	12/2024
7 Warnings and Precautions, 7.1.6 Hepatic/ Biliary/ Pancreatic	08/2026
7 Warnings and Precautions, 7.1.7 Renal insufficiency	08/2026

Table of Contents

Certain sections or subsections that are not applicable at the time of the preparation of the most recent authorized product monograph are not listed.

Recent Major Label Changes	2
Table of Contents	2
Part 1: Healthcare Professional Information.....	5
1. Indications	5
1.1. Pediatrics	5
1.2. Geriatrics	5
2. Contraindications	5
3. Serious Warnings and Precautions Box	6
4. Dosage and Administration	6
4.1. Dosing Considerations	6
4.2. Recommended Dose and Dosage Adjustment.....	6
4.4. Administration	7
4.5. Missed Dose	8
5. Overdose	8

6. Dosage Forms, Strengths, Composition, and Packaging	8
7. Warnings and Precautions	8
Driving and Operating Machinery	8
Hematologic	9
Monitoring and Laboratory Tests	10
Reproductive Health	10
Respiratory	10
7.1. Special Populations	11
7.1.1. Pregnancy	11
7.1.2. Breastfeeding	11
7.1.3. Pediatrics	11
7.1.4. Geriatrics	12
7.1.5. UGT2B17 and CYP2C19 Poor Metabolizers	12
7.1.6. Hepatic/ Biliary/ pancreatic	12
7.1.7. Renal insufficiency	12
8. Adverse Reactions	13
8.1. Adverse Reaction Overview	13
8.2. Clinical Trial Adverse Reactions	14
8.3. Less Common Clinical Trial Adverse Reactions	18
8.4. Abnormal Laboratory Findings: Hematologic, Clinical Chemistry, and Other Quantitative Data	20
8.5. Post-Market Adverse Reactions	22
9. Drug Interactions	22
9.2. Drug Interactions Overview	22
9.4. Drug-Drug Interactions	22
9.5. Drug-Food Interactions	23
9.6. Drug-Herb Interactions	23
9.7. Drug-Laboratory Test Interactions	23
10. Clinical Pharmacology	23
10.1. Mechanism of Action	23
10.2. Pharmacodynamics	23

10.3. Pharmacokinetics	24
11. Storage, Stability, and Disposal	26
Part 2: Scientific Information	27
13. Pharmaceutical Information.....	27
14. Clinical Trials.....	27
14.1. Clinical Trials by Indication	27
Von Hippel-Lindau (VHL) disease-associated renal cell carcinoma (RCC), central nervous system (CNS) hemangioblastomas and pancreatic neuroendocrine tumours (pNETs)	27
Renal cell carcinoma (RCC)	29
15. Microbiology.....	32
16. Non-Clinical Toxicology	32
Patient Medication Information.....	34

Part 1: Healthcare Professional Information

1. Indications

WELIREG® (belzutifan) is indicated for:

Von Hippel-Lindau (VHL) disease

WELIREG® is indicated for the treatment of adult patients with von Hippel-Lindau (VHL) disease who require therapy for associated non-metastatic renal cell carcinoma (RCC), central nervous system (CNS) hemangioblastomas, or non-metastatic pancreatic neuroendocrine tumors (pNET), not requiring immediate surgery.

Efficacy in patients with VHL disease-associated RCC, CNS hemangioblastomas, or pNET was based on objective response rate and duration of response in a single-arm study (see [14 Clinical Trials](#)).

Renal Cell Carcinoma

WELIREG® is indicated for the treatment of adult patients with advanced renal cell carcinoma (RCC) following a programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor and a vascular endothelial growth factor tyrosine kinase inhibitor (VEGF-TKI).

1.1. Pediatrics

Pediatrics (< 18 years of age): No data are available to Health Canada; therefore, Health Canada has not authorized an indication for pediatric use.

1.2. Geriatrics

Geriatrics (≥ 65 years of age):

Of the 372 participants who received WELIREG® in LITESPARK-005, 62% of participants were < 65 years, 28% of participants were 65 to 74 years, and 10% were ≥ 75 years. No overall difference in safety or efficacy was reported between patients who were 65 years and over and younger patients. Differences in WELIREG® tolerability profile were observed in patients who were ≥ 65 years compared to younger patients (See 7.1.4 WARNINGS AND PRECAUTIONS, geriatrics).

2. Contraindications

- WELIREG® is contraindicated in patients who are hypersensitive to this drug or to any ingredient in the formulation, including any non-medicinal ingredient, or component of the container. For a complete listing, see [6 Dosage Forms, Strengths, Composition and Packaging](#).

3. Serious Warnings and Precautions Box

Embryo-fetal toxicity (see [7 Warnings and Precautions](#), [16 Non-Clinical Toxicology](#))

- Exposure to WELIREG® during pregnancy can cause embryo-fetal harm.
- Verify pregnancy status prior to the initiation of WELIREG®.
- Advise patients of these risks and the need for effective non-hormonal contraception.
- WELIREG® can render hormonal contraceptives ineffective (see [9 Drug Interactions](#))

4. Dosage and Administration

4.1. Dosing Considerations

- Verify the pregnancy status of females of reproductive potential prior to initiating treatment with WELIREG® (see [7 Warnings and Precautions](#), [Special Populations](#)).

4.2. Recommended Dose and Dosage Adjustment

The recommended dose of WELIREG® is 120 mg (three 40 mg tablets) administered orally once daily, with or without food (see [10.3 Pharmacokinetics](#)). Tablets should be swallowed whole. Treatment should continue until disease progression or unacceptable toxicity occurs.

Dose Modification Guidelines

Dosage modifications for WELIREG® for adverse reactions are summarized in Table 1.

The recommended dose reductions are:

- First dose reduction: WELIREG® 80 mg orally once daily
- Second dose reduction: WELIREG® 40 mg orally once daily
- Third dose reduction: Permanently discontinue

Table 1 - Recommended Dose Modifications for Adverse Reactions

Adverse Reactions	Severity*	Dose Modification
Anemia (see 7 Warnings and Precautions)	Grade 3 or transfusion indicated	• Withhold until resolved to ≤ Grade 2. • Resume at the same or reduced dose (reduce by 40 mg) or discontinue; consider discontinuing depending on the severity and persistence of anemia.
	Grade 4	• Withhold until resolved to ≤ Grade 2. • Resume at a reduced dose (reduce by 40 mg) or permanently discontinue upon recurrence of Grade 4.
Hypoxia (see 7 Warnings and Precautions)	Grade 2	• Consider whether to continue or withhold until resolved. • If withheld, consider resuming at a reduced dose depending on severity and persistence of hypoxia.

Adverse Reactions	Severity*	Dose Modification
	Grade 3	- Withhold until resolved. - Resume at reduced dose (reduce by 40 mg) or discontinue depending on the severity and persistence of hypoxia.
	Grade 4 or recurrent symptomatic hypoxia	Permanently discontinue.
Other Adverse Reactions (see 8 Adverse Reactions)	Grade 3	- Withhold dosing until symptoms improve to $\leq$ Grade 2. - Consider resuming at a reduced dose (reduce by 40 mg). - Permanently discontinue WELIREG® if Grade 3 adverse reaction recurs
	Grade 4	Permanently discontinue.

*Based on National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), version 5.0

Pediatrics: Health Canada has not authorized an indication for pediatric use.

Geriatrics (≥ 65 years of age): No dose adjustment is needed in patients ≥ 65 years of age (see [10 Clinical Pharmacology](#)).

Renal Insufficiency: No dose adjustment is recommended in patients with renal insufficiency including end-stage renal disease (see [10 Clinical Pharmacology](#)). For patients with severe renal impairment (eGFR 15-29 mL/min estimated by MDRD) monitor for increased adverse reactions and modify the dosages as recommended (see [4 Dosage and Administration](#) and [10 Clinical Pharmacology](#)).

Hepatic Insufficiency: No dose adjustment is recommended in patients with mild (total bilirubin $\leq$ upper limit of normal [ULN] and aspartate aminotransferase [AST] $>$ ULN or total bilirubin > 1 to $1.5 \times$ ULN and any AST) or moderate (total bilirubin within range of $> 1.5 \times$ ULN and $\leq 3 \times$ ULN and any AST or Child-Pugh B) hepatic insufficiency. WELIREG® has not been studied in patients with severe (total bilirubin $> 3 \times$ ULN and any AST) hepatic insufficiency (see [10 Clinical Pharmacology](#)). For patients with moderate and severe hepatic impairment, monitor for increased adverse reactions and modify the dosage as recommended (see [4 Dosage and Administration](#) and [10 Clinical Pharmacology](#)).

UGT2B17 and CYP2C19 Genetic Polymorphism: No dose adjustment is recommended for patients who are dual UGT2B17 and CYP2C19 poor metabolizers (see [7 Warnings and Precautions](#), [10 Clinical Pharmacology](#)).

4.4. Administration

WELIREG® is administered with or without food (see [10.3 Pharmacokinetics](#)). Tablets should be swallowed whole. Treatment should continue until disease progression or unacceptable toxicity occurs.

4.5. Missed Dose

If a dose of WELIREG® is missed, it can be taken as soon as possible on the same day. The regular daily dose schedule for WELIREG® should be resumed the next day. Extra tablets should not be taken to make up for the missed dose. If vomiting occurs any time after taking WELIREG®, the dose should not be retaken. The next dose should be taken the next day.

5. Overdose

There is no specific treatment for WELIREG® overdose. In cases of suspected overdose, if necessary, consider withholding WELIREG® and instituting supportive care. The highest dose of WELIREG® studied clinically was 600 mg total daily dose (200 mg three times a day). At doses of 320 mg to 600 mg daily in 26 patients, the most common adverse reactions were anemia (92%), dyspnea (42%) and fatigue (42%).

For the most recent information in the management of a suspected drug overdose, contact your regional poison control centre or Health Canada's toll-free number, 1-844 POISON-X (1-844-764-7669).

6. Dosage Forms, Strengths, Composition, and Packaging

Table 2– Dosage Forms, Strengths, and Composition

Route of Administration	Dosage Form/ Strength/Composition	Non-Medicinal Ingredients
oral	Tablet / 40 mg / belzutifan	croscarmellose sodium, FD&C Blue #2 aluminum lake, hypromellose acetate succinate, magnesium stearate, mannitol, microcrystalline cellulose, polyethylene glycol, polyvinyl alcohol, colloidal silicon dioxide, talc and titanium dioxide.

Description

40 mg tablets of WELIREG®: blue, oval, film-coated tablet with “177” on one side. Available in bottle of 90 tablets with desiccant and blisters of 90 tablets (3 cartons of 30 tablets inside of a larger, master carton).

7. Warnings and Precautions

See [3 Serious Warnings and Precautions box](#)

Driving and Operating Machinery

No studies on the effects on the ability to drive and use machines have been performed. Dizziness and

fatigue may occur following administration of WELIREG® which could influence the ability to drive or use machines (see [8 Adverse Reactions](#)).

Hematologic

Anemia:

WELIREG® can cause severe anemia that can require blood transfusion and erythropoiesis stimulating agents.

Monitor for anemia before initiation of and routinely throughout treatment with WELIREG®. For patients who develop Grade 3 anemia, withhold WELIREG® and treat according to standard medical practice until resolved to ≤ Grade 2; then resume at the same or reduced dose. For recurrent Grade 3 anemia, consider discontinuing WELIREG®. For patients who develop Grade 4 anemia, withhold WELIREG®; then resume at a reduced dose or permanently discontinue for recurrent Grade 4 anemia (see [4 Dosage and Administration, 4.2 Recommended Dose and Dosage Adjustment, 10.2 Pharmacodynamics](#)).

A significant baseline (≤ 120 g/L) effect was found for risk of developing ≥ Grade 3 anemia in a Phase 1 study.

von Hippel-Lindau (VHL) disease

In a clinical trial (LITESPARK-004) with WELIREG® for the treatment of patients with VHL disease-associated RCC, anemia was reported in 55 patients (90.2%). Grade 3 anemia occurred in 7 patients (11.5%) (see [8 Adverse Reactions](#)). Median time to onset of all Grade anemia events was 30 days (range: 1 day to 8.38 months). Of the 14 patients that were treated with an erythropoiesis-stimulating agent (ESA), 5 received treatment with both an ESA and blood transfusions, while 9 received treatment with an ESA alone.

The safety of erythropoiesis stimulating agents (ESAs) for treatment of anemia in patients with VHL disease treated with WELIREG® has not been established. Randomized controlled trials in patients with cancer receiving myelosuppressive chemotherapy with ESAs have shown that ESAs increased the risks of death and serious cardiovascular reactions, and decreased progression-free survival and/or overall survival. See the prescribing information for ESAs for more information.

Advanced renal cell carcinoma (RCC)

In LITESPARK-005, a clinical trial with WELIREG® for the treatment of patients with advanced RCC, anemia was reported in 83% of patients, 119 patients (32%) had Grade 3 and 2 patients (0.5%) had Grade 4 anemia (see [8 Adverse Reactions](#)). Median time to onset of anemia was 29 days (range: 1 day to 28 months). Of the patients with anemia, 22% received transfusions only, 20% received ESAs only and 14% received both transfusion and ESAs.

Monitoring and Laboratory Tests

Monitor oxygen saturation with pulse oximetry before initiation of and regularly at follow up visits throughout treatment with WELIREG®. Some patients may experience asymptomatic hypoxia; at their discretion, health care providers may instruct patients to monitor oxygen saturation at home.

Monitor for anemia before initiation of and routinely throughout treatment with WELIREG®.

Reproductive Health

See [3 SERIOUS WARNINGS AND PRECAUTIONS BOX](#) and [7.1.1 Pregnancy](#)

- **Fertility**

No data on the effects of WELIREG® on fertility in humans are available. Based on findings in animals, WELIREG® may impair fertility in males and females of reproductive potential (see [16 Non-Clinical Toxicology](#)). The reversibility of the effect on fertility is unknown. Advise patients of this potential risk. Family planning should be discussed with patients as appropriate.

- **Contraception**

Based on findings in animals, WELIREG® may cause fetal harm, including fetal loss, in humans (see [16 Non-Clinical Toxicology](#)). Advise females of reproductive potential to use highly effective non-hormonal contraceptive methods during treatment with WELIREG® and for at least 1 week after the last dose due to the potential risk to the fetus. Use of WELIREG® may reduce the effectiveness of hormonal contraceptives (see 9.4 Drug-Drug Interactions). Verify the pregnancy status of females of reproductive potential prior to initiating treatment with WELIREG®.

Advise male patients with female partners of reproductive potential to use highly effective contraceptive methods during treatment with WELIREG® and for at least 1 week after the last dose (see [7 Warnings and Precautions, Special Populations](#) and [16 Non-Clinical Toxicology](#)).

Respiratory

Hypoxia:

WELIREG® can cause severe hypoxia that may require discontinuation, supplemental oxygen, or hospitalization.

Monitor oxygen saturation with pulse oximetry before initiation of and regularly at follow up visits throughout treatment with WELIREG®. Some patients may experience asymptomatic hypoxia; at their discretion, health care providers may instruct patients to monitor oxygen saturation at home. For Grade 2 hypoxia, treat according to standard medical practice and consider whether to continue or withhold WELIREG® treatment. If withheld, consider resuming at a reduced dose depending on severity of hypoxia. For Grade 3 hypoxia, withhold WELIREG® until resolved and treat according to standard medical practice. Resume at reduced dose or discontinue depending on the severity of hypoxia. For recurrent hypoxia, discontinue treatment. For Grade 4 hypoxia or recurrent symptomatic hypoxia, permanently discontinue treatment (see [4 Dosage and Administration, 4.2 Recommended Dose and Dosage Adjustment](#)).

In a clinical trial (LITESPARK-004) with WELIREG® for the treatment of patients with VHL disease-associated RCC, Grade 3 hypoxia occurred in 1 patient (1.6%) (see [8 Adverse Reactions](#)). In LITESPARK-005, a clinical trial with WELIREG® for the treatment of patients with advanced RCC, hypoxia occurred in 15% of patients and 38 patients (10%) had Grade 3 hypoxia and 1 patient (0.3%) had Grade 4 hypoxia (see [8 Adverse Reactions](#)). Of the patients with hypoxia, 70% were treated with oxygen therapy. Median time to onset of hypoxia was 1 month (range: 1 day to 21 months).

7.1. Special Populations

7.1.1. Pregnancy

Embryo-Fetal Toxicity:

Based on findings in animal studies, WELIREG® may cause fetal harm, including fetal loss, when administered to a pregnant woman (see [16 Non-Clinical Toxicology](#)). There are no available data on the use of WELIREG® in pregnant women to evaluate drug-associated risk. Advise females of reproductive potential of the potential risk to a fetus.

The estimated background risk of major birth defects and miscarriage for the indicated population is unknown.

For information on contraception for patients who are females of child bearing potential or male patients, please refer to [7 Warnings and Precautions, Reproductive Health](#).

7.1.2. Breastfeeding

It is unknown if WELIREG® or its metabolites are excreted in human milk, and there are no data on their effects on the breastfed child, or on milk production. Precaution should be exercised because many drugs can be excreted in human milk. Because of the potential for serious adverse reactions in breastfed children, advise women not to breastfeed during treatment with WELIREG® and for at least 1 week after the last dose.

7.1.3. Pediatrics

Pediatrics (< 18 years of age): Safety and effectiveness of WELIREG® in pediatric patients under 18 years of age have not been established.

7.1.4. Geriatrics

Geriatrics (≥ 65 years of age): Based on population PK modeling, no dosage adjustment is recommended in geriatric patients (see [10 Clinical Pharmacology](#)). There were 2 (3.3%) patients with VHL disease-associated RCC ≥65 years of age in the Phase 2 LITESPARK-004 (see [14 Clinical Trials](#)). Clinical trials of WELIREG® in patients with VHL did not include sufficient numbers of patients aged 65 and older to determine whether they respond differently from younger patients.

Of the patients with advanced RCC who received WELIREG® in LITESPARK-005, 62% of participants were < 65 years, 28% of participants were 65 to 74 years, and 10% were ≥ 75 years old (see [14 Clinical Trials](#)). Dose interruptions occurred in 53% of patients who were ≥65 years and in 38% of younger patients. Dose reductions occurred in 19% of patients who were ≥65 years and in 11% of younger patients. No overall difference in safety or efficacy was reported between patients who were 65 years and over and younger patients.

7.1.5. UGT2B17 and CYP2C19 Poor Metabolizers

Patients who are either UGT2B17 poor metabolizers or dual UGT2B17 and CYP2C19 poor metabolizers have higher belzutifan exposures, which may increase the incidence and severity of adverse reactions of WELIREG®. The estimated frequencies of either UGT2B17 poor metabolizers or dual CYP2C19 and UGT2B17 poor metabolizers are higher in Asians compared to Caucasians and African Americans. Closely monitor for adverse reactions in patients who are either UGT2B17 poor metabolizers or dual UGT2B17 and CYP2C19 poor metabolizers (see [4 Dosage and Administration](#), [9 Drug Interactions](#), [9.4 Drug-Drug Interactions](#), [10.2 Pharmacodynamics](#), and [10.3 Pharmacokinetics](#)).

7.1.6. Hepatic/ Biliary/ pancreatic

No dose adjustment of WELIREG® is recommended in patients with mild (total bilirubin ≤ upper limit of normal [ULN] and aspartate aminotransferase [AST] > ULN or total bilirubin > 1 to 1.5 x ULN and any AST) or moderate (total bilirubin within range of > 1.5 x ULN and ≤ 3 x ULN and any AST or Child-Pugh B) hepatic impairment. WELIREG® has not been studied in patients with severe hepatic insufficiency (see [4 Dosage and Administration](#), [Hepatic Insufficiency](#) and [10.3 Pharmacokinetics](#)). For patients with moderate and severe hepatic impairment, monitor for increased adverse reactions and modify the dosage as recommended (see [4 Dosage and Administration](#) and [10 Clinical Pharmacology](#)).

7.1.7. Renal insufficiency

No dose adjustment of WELIREG® is recommended in patients with renal impairment including end-stage renal disease. (see [4 Dosage and Administration](#), [Renal Insufficiency](#) and [10.3 Pharmacokinetics](#)). For patients with severe renal impairment (eGFR 15-29 mL/min estimated by MDRD) monitor for increased adverse reactions and modify the dosage as recommended (see [4 Dosage and Administration](#) and [10 Clinical Pharmacology](#)).

8. Adverse Reactions

8.1. Adverse Reaction Overview

The following clinically significant adverse reactions are discussed elsewhere in the labeling (see [7 Warnings and Precautions](#)):

- Anemia (see [7 Warnings and Precautions](#))
- Hypoxia (see [7 Warnings and Precautions](#))

Von Hippel-Lindau (VHL) disease-associated renal cell carcinoma (RCC), central nervous system (CNS) hemangioblastomas and pancreatic neuroendocrine tumours (pNETs)

The safety of WELIREG[®] was evaluated in an open-label single-arm Phase 2 clinical study (LITESPARK-004), in 61 patients with VHL disease-associated RCC and who did not require immediate surgery. Enrolled participants included those with other VHL disease-associated tumours such as pancreatic lesions, pancreatic neuroendocrine tumours (pNETs), central nervous system hemangioblastomas (CNS HB) and retinal hemangioblastomas. Patients were treated with 120 mg WELIREG[®] once daily. The median duration of exposure to WELIREG[®] was 37.3 months (range 1.9 to 46.1 months) with 90% exposed for 18 months or longer.

Treatment-Emergent Adverse Events

In the pivotal LITESPARK-004, a treatment-emergent adverse event (TEAE) was reported by all 61 patients who received WELIREG[®]. The most common TEAEs (incidence $\geq 20\%$) under treatment with WELIREG[®] were anemia (90.2%), fatigue (73.8%), headache (47.5%), dizziness (45.9%), nausea (39.3%), dyspnea (26.2%), myalgia (24.6%), constipation (23.0%), arthralgia (21.3%) and vision blurred (21.3%).

Grade ≥ 3 TEAE occurred in 44.3% of patients, with Grade 3, Grade 4, and Grade 5 TEAEs observed in 36.1%, 4.9%, and 3.3%, respectively. The most common Grade ≥ 3 TEAEs were anemia (11.5%), hypertension (9.8%), and fatigue (4.9%). There were 3 (4.9%) Grade 4 TEAEs (embolism, retinal detachment, and retinal vein occlusion) and 2 (3.3%) Grade 5 TEAEs (suicide attempt and toxicity to various agents).

Serious TEAE were reported in 29.5% of patients; the only SAEs reported by more than 1 participant were hemorrhage intracranial and embolism (2 participants with VHL-CNS HB [3.3%] each).

The most frequently ($\geq 3\%$) reported TEAEs leading to treatment interruption were fatigue (11.5%), nausea (9.8%), headache (6.6%), dizziness (4.9%), influenza-like illness (4.9%), abdominal pain (3.3%), anemia (3.3%), COVID-19 (3.3%), haemorrhage intracranial (3.3%), syncope (3.3%) and vomiting (3.3%).

The most common TEAE resulting in dose reduction of WELIREG[®] were fatigue (8.2%) and anemia (3.3%). No other AEs that led to dose reduction were reported by more than 1 patient.

TEAE resulted in the permanent discontinuation of WELIREG[®] for 4 patients (6.6%) (Grade 1 dizziness, Grade 2 hemorrhage intracranial, Grade 5 toxicity to various agents, Grade 5 suicide attempt).

Renal cell carcinoma (RCC)

The safety of WELIREG[®] was evaluated in a phase 3, open-label, active-controlled study (LITESPARK-005) in 732 patients with advanced RCC that has progressed after prior programmed cell death 1/ligand 1 (PD-1/L1) and vascular endothelial growth factor (VEGF)-targeted therapies. Patients received 120 mg

WELIREG® (n=372) or 10 mg everolimus (n=360) by oral administration once daily. The median duration of exposure to WELIREG® was 7.6 months (range: 0.1 to 36 months) and the median duration of exposure to everolimus was 3.9 months (range 0 to 33 months).

Treatment-Emergent Adverse Events

The most common TEAEs (incidence ≥20%) under treatment with WELIREG® were anemia (83%), fatigue (46%), musculoskeletal pain (38%) and edema (20%).

Serious TEAE's occurred in 42% of patients who received WELIREG® and 38% of participants who received everolimus. Serious adverse events in ≥2% of patients and more frequently reported in the WELIREG® treated group compared to everolimus group were hypoxia (7.5% vs. 0%), anemia (5.4% vs. 2.2%), pneumonia (4.8% vs. 5.6%) and hemorrhage (3.0% vs. 0.6%).

Permanent discontinuation due to TEAE's occurred in 6% of patients in the WELIREG® treated group and 15% of patients in the everolimus group. The most common TEAE's which resulted in permanent discontinuation in the WELIREG® treated group compared to the everolimus group was hypoxia (0.8% vs. 0.0%).

Dose interruptions of WELIREG® due to a TEAE occurred in 44% of patients. The most common TEAE's which required dosage interruption in ≥1% of patients in the WELIREG®-treated group were anemia (9%), hypoxia (5.6%), COVID-19 (5.1%), fatigue (3.2%), pneumonia (2.7%), diarrhea (2.2%), hemorrhage (2.2%), dizziness (1.9%), dyspnea (1.9%), pleural effusion (1.9%), nausea (1.3%), pyrexia (1.3%), spinal cord compression (1.1%), abdominal pain (1.1%) and rash (1.1%). Dose interruptions were observed in 26% (13 of 51) of the Asian population compared to 22% (64 of 294) of the Caucasian population (see [10.2 Pharmacodynamics](#) and [10.3 Pharmacokinetics](#)).

Dose reductions of WELIREG® due to a TEAE occurred in 14% of patients. The most TEAE's (≥1%) in the WELIREG®-treated group were hypoxia (5.6%), anemia (3%), and fatigue (1.1%).

Dose reductions were observed in 24% (12 of 51) of the Asian population compared to 10% (30 of 294) of the Caucasian population (see [10.2 Pharmacodynamics](#) and [10.3 Pharmacokinetics](#)).

8.2. Clinical Trial Adverse Reactions

Clinical trials are conducted under very specific conditions. Therefore, the frequencies of adverse reactions observed in the clinical trials may not reflect frequencies observed in clinical practice and should not be compared to frequencies reported in clinical trials of another drug.

Patients with Von Hippel-Lindau (VHL) disease-associated renal cell carcinoma (RCC), central nervous system (CNS) hemangioblastomas and pancreatic neuroendocrine tumours (pNETs)

The safety of WELIREG® was evaluated in all 61 patients enrolled in the pivotal single-arm Phase 2 clinical study (LITESPARK-004) with VHL disease-associated non-metastatic RCC who received at least one dose of WELIREG® monotherapy at a dose of 120 mg. In LITESPARK-004, the median duration of exposure was 37.3 months (range 1.9 to 46.1 months). The median age was 41 years (range 19 to 66 years), with 3.3% of patients ≥ 65 years of age. Treatment-emergent adverse events that were reported in ≥10% of patients are listed in the Table 3.

Table 3 – Treatment-Emergent Adverse Events Occurring in ≥ 10 % of Patients Treated with WELIREG® (LITESPARK-004)

	WELIREG® N= 61	
	All Grades n (%)	Grade 3-4 n (%)
Blood and lymphatic disorders		
Anemia	55 (90)	7 (11)
Eye Disorders		
Visual impairment [†]	17 (28)	2 (3)
Gastrointestinal disorders		
Nausea	24 (39)	0
Constipation	14 (23)	0
Abdominal pain [‡]	14 (23)	0
Diarrhea	11 (18)	1 (2)
Vomiting	7 (11)	0
General disorders and administration site disorders		
Fatigue [§]	46 (75)	3 (5)
Edema peripheral	9 (15)	0
Infections		
COVID-19 ^a	8 (13)	1 (2)
Upper respiratory tract infections [¶]	14 (23)	0
Urinary tract infection	8 (13)	1 (2)
Investigations		
Alanine aminotransferase increased	12 (20)	0
Weight increased	10 (16)	1 (2)
Aspartate aminotransferase increased	7 (11)	0
Blood creatinine increased	7 (11)	0
Musculoskeletal and connective tissue disorders		
Arthralgia	13 (21)	0
Back pain	11 (18)	0
Myalgia	15 (25)	1 (2)
Muscle spasms	7 (11)	0

	WELIREG® N= 61	
Nervous system disorders		
Headache [#]	30 (49)	0
Dizziness ^p	28 (46)	0
Disturbance in attention	8 (13)	0
Psychiatric Disorder		
Insomnia	9 (15)	0
Anxiety	7 (11)	0
Respiratory, thoracic and mediastinal disorders		
Dyspnea	16 (26)	1 (2)
Cough	7 (11)	0
Vascular disorders		
Hypertension	9 (15)	6 (10)

[†] includes visual impairment, vision blurred, retinal vein occlusion and retinal detachment

[‡] includes abdominal discomfort, abdominal pain, abdominal pain upper and abdominal pain lower

[§] includes fatigue and asthenia

[¶] includes bronchitis, sinusitis, upper respiratory tract infection and viral upper respiratory tract infection

[#] includes headache and migraine

^p includes dizziness and vertigo

^a includes COVID-19, COVID-19 pneumonia, and post-acute COVID-19 syndrome

In a clinical study (LITESPARK-004) with WELIREG® for the treatment of patients with VHL disease-associated RCC, Grade 3 hypoxia occurred in 1 patient (1.6%). This case of hypoxia occurred within 2 months of treatment initiation in a patient with previously undiagnosed restrictive lung disease and was asymptomatic. This patient did not receive supplemental oxygen and was managed with dose reduction to 80 mg QD with no recurrence of hypoxia. In another clinical study (Study-001) for the treatment of non-VHL disease-associated advanced solid tumors using the same dose of WELIREG®, hypoxia occurred in 18 patients (31%), with Grade 3 hypoxia occurring in 12 patients (20.7%).

Renal cell carcinoma (RCC)

- The most common treatment-emergent adverse events (≥10%) in the WELIREG®-treated group in LITESPARK-005 are listed in Table 4.

Table 4 – Treatment-Emergent Adverse Events in ≥10 % of Patients Treated with WELIREG® in LITESPARK-005

	WELIREG® n=372		Everolimus n=360	
	All Grades n (%)	Grade 3-4 n (%)	All Grades n (%)	Grade 3-4 n (%)

	WELIREG® n=372		Everolimus n=360	
Blood and lymphatic disorders				
Anemia*	309 (83)	121(33)	205 (57)	65 (18)
Gastrointestinal disorders				
Nausea	67 (18)	2 (1)	41(11)	1 (0)
Constipation	62 (17)	0 (0)	29 (8)	0 (0)
Vomiting	48 (13)	3 (1)	32 (9)	3 (1)
Diarrhea ^a	45 (12)	5 (1)	71 (20)	6 (2)
Abdominal pain ^e	40 (11)	4 (1)	30 (8)	1 (0)
General disorders and administration disorders				
Fatigue ^s	171 (46)	13 (3)	151 (42)	17 (5)
Oedema [†]	76 (20)	2 (1)	83 (21)	2 (1)
Infections and infestations				
COVID-19	41 (11)	7 (2)	42 (12)	17 (5)
Metabolism and nutrition disorders				
Decreased appetite	54 (15)	4 (1)	57 (16)	0 (0)
Musculoskeletal and Connective Tissue				
Musculoskeletal pain [‡]	140 (38)	6 (2)	103 (29)	8 (2)
Nervous system disorders				
Dizziness ^a	51 (14)	0 (0)	9 (3)	0 (0)
Headache [§]	46 (12)	2 (1)	27 (8)	1 (0)
Respiratory, thoracic and mediastinal disorders				
Dyspnoea [°]	63 (17)	6 (2)	59 (16)	10 (3)
Hypoxia	54 (15)	39 (11)	4 (1)	4 (1)
Vascular disorders				
Hemorrhage ^β	39 (10)	10 (3)	39 (11)	2 (1)

* includes anemia and hemoglobin decreased

[†] includes diarrhea, colitis, and enterocolitis

[‡] includes abdominal pain, abdominal pain lower, abdominal pain upper, abdominal discomfort, epigastric discomfort, and gastrointestinal pain

[§] includes fatigue, asthenia and lethargy

[¶] includes oedema peripheral, face oedema, generalised oedema, oedema, periorbital oedema, eyelid oedema, localised oedema, oedema genital, eye oedema, and swelling

[#] includes COVID-19 and COVID-19 pneumonia

^p includes musculoskeletal chest pain, back pain, bone pain, pain in extremity, spinal pain, arthralgia, myalgia, musculoskeletal pain, non-cardiac chest pain, neck pain, arthritis, musculoskeletal discomfort, and musculoskeletal stiffness

^a includes dizziness and vertigo

^e includes headache and migraine

^o includes dyspnoea and dyspnoea exertional

^β includes haematuria, haemoptysis, epistaxis, gingival bleeding, gastrointestinal haemorrhage, haemorrhage intracranial, rectal haemorrhage, upper gastrointestinal haemorrhage, cerebral haemorrhage, small intestinal haemorrhage, anal haemorrhage, intra-abdominal haemorrhage, pericardial haemorrhage, pulmonary haemorrhage, and vitreous haemorrhage

Graded per NCI CTCAE v5.0

8.3. Less Common Clinical Trial Adverse Reactions

Patients with Von Hippel-Lindau (VHL) disease-associated renal cell carcinoma (RCC), central nervous system (CNS) hemangioblastomas and pancreatic neuroendocrine tumours (pNETs)

The following terms are treatment-emergent adverse events reported at an incidence of $\geq 1\%$ and $< 10\%$ in LITESPARK-004.

Blood and lymphatic system disorder: hypotransferrinaemia, lymphadenopathy

Cardiac disorders: sinus bradycardia, pericardial effusion, sinus tachycardia, angina pectoris, coronary artery dissection, left ventricular dysfunction, tachycardia, palpitations, atrial enlargement

Ear and labyrinth disorders: tinnitus, external ear pain, ear pain, eustachian tube dysfunction, excessive cerumen production, hypoacusis, mastoid effusion, middle ear effusion, ear discomfort, external ear inflammation, middle ear inflammation

Endocrine disorders: hypothyroidism, adrenal insufficiency

Eye Disorders: dry eye, lacrimation increased, diplopia, conjunctival hemorrhage, eye irritation, photophobia, vitreous floaters, blepharitis, myopia, ocular discomfort, periorbital oedema, presbyopia, retinal-hemorrhage, retinal vascular disorder, eye pain, vitreous hemorrhage

Gastrointestinal disorders: stomatitis, abdominal distension, gastritis, oral pain, aphthous ulcer, colitis, mouth cyst, dry mouth, dyspepsia, gastro esophageal reflux disease, hemorrhoidal hemorrhage, hemorrhoids, lip edema

General disorders and administration site conditions: non-cardiac chest pain, chills, malaise, gait disturbance, complication associated with device, localised oedema, drug interaction, feeling abnormal, generalised oedema, peripheral swelling, sensation of foreign body, temperature intolerance, chest discomfort, pain, nodule, pyrexia, chest pain, influenza like illness

Hepatobiliary disorders: biliary colic

Immune system disorders: seasonal allergy, contrast media allergy, hypersensitivity, anaphylactic reaction

Infections and infestations: conjunctivitis, otitis media, influenza, cystitis, diverticulitis, rhinitis, viral infection, hordeolum, herpes zoster, body tinea, borrelia infection, eye infection, folliculitis, gastroenteritis viral, helicobacter infection, herpes simplex reactivation, nail infection, nasopharyngitis, respiratory tract infection, scrotal infection, tonsillitis streptococcal, urinary tract infection enterococcal, cellulitis, otitis media chronic, pneumonia, rash pustular

Injury, poisoning and procedural complications: fall, contusion, arthropod sting, exposure to communicable disease, face injury, incision site pain, muscle rupture, ocular procedural complication, rib fracture, skin laceration, thermal burn, toxicity to various agents, ligament sprain, procedural pain, spinal fracture

Investigations: white blood cell count decreased, neutrophil count decreased, blood cholesterol increased, reticulocyte count decreased, lymphocyte count decreased, platelet count decreased, blood bilirubin increased, amylase increased, blood iron decreased, epinephrine increased, glomerular filtration rate decreased, nitrite urine present, right ventricular systolic pressure increased, weight decreased, blood alkaline phosphatase increased, intraocular pressure increased, lipase increased, SARS-CoV-2 test positive

Metabolism and nutrition disorders: decreased appetite, hyperglycaemia, hypermagnesaemia, hypoglycaemia, dehydration, hyperkalaemia, hypophosphataemia, hyponatraemia, vitamin D deficiency, hypokalemia, diabetes mellitus, iron deficiency

Musculoskeletal and connective tissue disorders: neck pain, muscular weakness, musculoskeletal chest pain, musculoskeletal pain, pain in jaw, joint effusion, flank pain, pain in extremity

Neoplasms benign, malignant and unspecified: vulval cancer, non-small cell lung cancer

Nervous system disorders: dysgeusia, syncope, tremor, hyperaesthesia, hypoaesthesia, peripheral sensory neuropathy, somnolence, presyncope, depressed level of consciousness, seizure, cognitive disorder, dysaesthesia, memory impairment, hemorrhage intracranial, loss of consciousness, neuralgia, sciatica, paraesthesia, aphasia, dysarthria, hemiparaesthesia, peroneal nerve palsy, restless legs syndrome

Product issues: device dislocation

Psychiatric disorders: depressed mood, dysphoria, major depression, mood altered, depression, attention deficit hyperactivity disorder, hypnopompic hallucination, suicide attempt

Renal and urinary disorders: pollakiuria, micturition urgency, renal pain, acute kidney injury, nocturia, haematuria, urinary incontinence, bladder spasm, nephrolithiasis, urine flow decreased

Reproductive system and breast disorders: pelvic pain, dysmenorrhoea, menopausal symptoms, vaginal lesion, vulvovaginal dryness, azoospermia, heavy menstrual bleeding, abnormal uterine bleeding, breast mass, erectile dysfunction, gynecomastia, menstruation irregular, ovarian cyst, testicular atrophy

Respiratory, thoracic and mediastinal disorders: upper-airway cough syndrome, hypoxia, dysphonia, epistaxis, tonsillar hypertrophy, oropharyngeal pain, nasal congestion, rhinitis allergic

Skin and subcutaneous tissue disorders: pruritus, rash maculo-papular, rash, decubitus ulcer, dermatitis acneiform, skin disorder, skin exfoliation, alopecia, blister, dermatitis contact, mucocutaneous rash, nail ridging, onycholysis, rash pruritic, skin discolouration, skin odour abnormal, sweat gland disorder, urticaria, xeroderma, dry skin, petechia

Surgical and medical procedures: cholecystectomy

Vascular disorders: hypotension, orthostatic hypotension, hot flush, embolism

Renal cell carcinoma (RCC)

The following terms are treatment emergent adverse events in LITESPARK-005 at an incidence $\geq 1\%$ and $< 10\%$ in the WELIREG arm. Clinically relevant TEAE's ($> 5\%$ difference between arms) were labelled with the incidence reported across treatment arms.

Blood and lymphatic system disorder: thrombocytopenia, neutropenia

Cardiac disorders: palpitations, tachycardia, atrial fibrillation, cardiac failure

Ear and labyrinth disorders: tinnitus, vertigo

Endocrine disorders: hypothyroidism

Eye Disorders: vision impairment (7.5% in WELIREG arm vs. 1.7% in everolimus arm, including vision blurred, cataract, visual acuity decreased, visual impairment, retinal detachment), dry eye

Gastrointestinal disorders: stomatitis, abdominal distension, dyspepsia, dry mouth, gastroesophageal reflux disease, dysphagia, oral pain

General disorders and administration site conditions pyrexia, chest pain, malaise, chest discomfort, influenza like illness, peripheral swelling, pain, xerosis, chills

Investigations: weight increased (5.9% in WELIREG arm vs. 0.8% in everolimus arm), weight decreased

Infections and infestations: pneumonia (including pneumonia, atypical pneumonia and lower respiratory tract infection), urinary tract infection, herpes zoster, upper respiratory infection, infection, nasopharyngitis

Injury, poisoning and procedural complications: fall, spinal compression fracture

Hepatobiliary disorders: hypertransaminasemia

Metabolism and nutrition disorders: acidosis, diabetes mellitus

Musculoskeletal and connective tissue disorders: muscle spasms, muscular weakness, flank pain, groin pain, joint swelling, osteoarthritis, rotator cuff syndrome

Nervous system disorders: paraesthesia, neuropathy peripheral, seizure, spinal cord compression, tremor, hemiparesis, memory impairment, somnolence, syncope,

Neoplasms benign, malignant, and unspecified: cancer pain, tumor pain

Psychiatric disorders: insomnia, anxiety, confusional state, depression, irritability

Renal and urinary disorders: proteinuria, dysuria, pollakiuria, renal failure, urinary retention

Respiratory, thoracic and mediastinal disorders: cough, pleural effusion, pulmonary embolism, dysphonia, nasal congestion, sleep apnea syndrome

Skin and subcutaneous tissue disorders: pruritus, dry skin, palmar-plantar erythrodysesthesia syndrome, hyperhidrosis, skin ulcer

Vascular disorders: hypertension, hypotension

8.4. Abnormal Laboratory Findings: Hematologic, Clinical Chemistry, and Other Quantitative Data

Clinical Trial Findings

Patients with Von Hippel-Lindau (VHL) disease-associated renal cell carcinoma (RCC), central nervous system (CNS) hemangioblastomas and pancreatic neuroendocrine tumours (pNETs)

Clinically relevant laboratory abnormalities are shown in Table 5.

Table 5 - Select Laboratory Abnormalities (> 10%) That Worsened from Baseline in Patients Who Received WELIREG® in LITESPARK-004

Laboratory Abnormality*	WELIREG® (N=61)	
	Grades 1-4 (%)	Grades 3-4 (%)
Chemistry		
Increased creatinine	67	0
Increased glucose	56	7
Increased potassium	13	0
Increased ALT	21	0

Increased AST	18	0
Decreased calcium (corrected)	11	0
Decreased phosphate	11	2
Magnesium increase	31	2
Sodium increase	11	0
Hematology		
Decreased hemoglobin	93	10
Decreased leukocytes	13	0
Decreased platelets	11	0
Lymphocytes Decreased (Lymphocyte count decrease)	38	2

*The denominator used to calculate the rate is based on all patients in the safety analysis population.

Advanced renal cell carcinoma (RCC) following immune and anti-angiogenic therapies

Clinically relevant laboratory abnormalities (worsened from baseline in $\geq 20\%$ of patients) in patients who received WELIREG® in LITESPARK-005 are shown in Table 6.

Table 6 - Select Laboratory Abnormalities ($\geq 20\%$) That Worsened from Baseline in Patients Who Received WELIREG® in LITESPARK-005

Laboratory Test*	WELIREG®		Everolimus	
	All Grades [†] %	Grades 3-4 %	All Grades [†] %	Grades 3-4 %
Chemistry				
Increased creatinine	35.2	1.9	43.9	3.4
Increased alanine aminotransferase	34.3	3.0	40.5	1.1
Decreased albumin	20.8	1.1	24.2	0.6
Decreased sodium	33.2	1.4	36.9	0.6
Increased potassium	31.3	3.0	20.6	2.8
Increased aspartate aminotransferase	29.4	3.0	38.4	2.0
Decreased calcium	24.2	1.1	45.4	3.1
Decreased glucose	22.4	1.1	18.9	1.1
Hematology				
Decreased hemoglobin	88.0	28.3	76.1	17.1
Decreased lymphocytes	35.7	7.8	53.0	19.7

Each test incidence is based on the number of patients who had both baseline and at least one on-study laboratory measurement available WELIREG® (range: 361 to 367 patients), and everolimus (range: 351 to 356 patients)

[†] Graded per NCI CTCAE v5.0

8.5. Post-Market Adverse Reactions

Not applicable.

9. Drug Interactions

9.2. Drug Interactions Overview

In vitro and pharmacogenomic studies indicate that WELIREG® is metabolized by UGT2B17 and by CYP2C19.

In Vitro Assessment of Drug Interactions

WELIREG® is a substrate of UGT2B17, CYP2C19 and CYP3A4. WELIREG® is not an inhibitor of CYP enzymes (CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, or CYP3A4). WELIREG® is a weak substrate of P-gp, OATP1B1 and OATP1B3. WELIREG® does not induce CYP1A2; however, WELIREG® induces CYP3A4 and CYP2B6 in a concentration dependent manner. WELIREG® does not inhibit the transporters P-gp, BCRP, OATP1B1, OATP1B3, OAT1, OAT3, OCT2, or MATE1, but does inhibit MATE2K. Inhibition of OCT1 cannot be ruled out.

9.4. Drug-Drug Interactions

Effects of WELIREG® on Other Drugs

Sensitive CYP3A4 Substrates

Coadministration of WELIREG® with CYP3A4 substrates decreases concentrations of CYP3A substrates (see [10 Clinical Pharmacology](#)), which may reduce the efficacy of these substrates. The magnitude of this decrease may be more pronounced in patients who are dual UGT2B17 and CYP2C19 poor metabolizers (see [10 Clinical Pharmacology](#)). Avoid coadministration of WELIREG® with sensitive CYP3A4 substrates, for which minimal decrease in concentration may lead to therapeutic failures of the substrate. If coadministration cannot be avoided, increase the sensitive CYP3A4 substrate dosage in accordance with its Prescribing Information.

Hormonal Contraceptives

Coadministration of WELIREG® with hormonal contraceptives may lead to contraceptive failure or an increase in breakthrough bleeding (see [7 Warnings and Precautions](#), [Reproductive Health](#), and [7.1.1 Pregnant Women](#)).

Effects of Other Drugs on WELIREG®

UGT2B17 or CYP2C19 Inhibitors

Coadministration of WELIREG® with inhibitors of UGT2B17 or CYP2C19 increases plasma exposure of belzutifan (see [10 Clinical Pharmacology](#)), which may increase the incidence and severity of adverse reactions of WELIREG®. Monitor for anemia and hypoxia and reduce the dosage of WELIREG® as recommended (see [4 Dosage and Administration](#) and [7 Warnings and Precautions](#)).

Based on physiologically-based PK modeling in patients with reduced activity of both UGT2B17 and CYP2C19, coadministration of WELIREG® with CYP3A4 inhibitors is expected to increase the plasma exposure of belzutifan, which may increase the risk of adverse reactions of WELIREG®. Monitor for

anemia and hypoxia and reduce the dosage of WELIREG® as recommended (see [4 Dosage and Administration](#) and [4.2 Recommended Dose and Dosage Adjustment](#)).

9.5. Drug-Food Interactions

A high fat, high-calorie meal delayed WELIREG® Tmax but had no clinically meaningful effect on exposure (see [10.3 Pharmacokinetics, Food Effect](#)). Interactions with other foods have not been established.

9.6. Drug-Herb Interactions

Interactions with herbal products have not been established.

9.7. Drug-Laboratory Test Interactions

Interactions with laboratory tests have not been established.

10. Clinical Pharmacology

10.1. Mechanism of Action

Belzutifan is an inhibitor of hypoxia-inducible factor 2 alpha (HIF-2 α), a transcription factor that plays a role in oxygen sensing by regulating genes that promote adaptation to hypoxia. Under normal oxygen levels, HIF-2 α is targeted for ubiquitin-proteasomal degradation by VHL protein. Hypoxia or gene alterations in VHL result in stabilization and accumulation of HIF-2 α . Upon stabilization, HIF-2 α translocates into the nucleus and interacts with hypoxia-inducible factor 1 beta (HIF-1 β) to form a transcriptional complex that regulates expression of downstream genes, including genes associated with cellular proliferation, angiogenesis, and tumor growth. Belzutifan binds to HIF-2 α and in conditions of hypoxia or impairment of VHL protein function, belzutifan blocks the HIF-2 α -HIF-1 β interaction, leading to reduced expression of HIF-2 α target genes. In vivo, belzutifan demonstrated anti-tumor activity in mouse xenograft models of renal cell carcinoma.

10.2. Pharmacodynamics

Treatment with WELIREG® in patients with VHL disease-associated RCC and in those with non-VHL disease-associated advanced solid tumors resulted in reductions in plasma levels of erythropoietin (EPO) which were observed to be dose- and/or exposure-dependent up to 120 mg once daily. Peak EPO suppression occurred at 2 weeks of treatment (mean of approximately 60% decrease from baseline). Mean EPO levels for VHL disease-associated RCC patients gradually returned to baseline values after 12 weeks of treatment. The incidence of Grade 3 anemia increased with higher exposure in patients with baseline hemoglobin levels < 120 g/L (see [7 Warnings and Precautions](#)).

Cardiac Electrophysiology

At the recommended dose (120 mg once daily) for WELIREG®, there were no clinically relevant effects on the QTc interval. Based on concentration-QTc modeling in LITESPARK-004, the predicted mean change from baseline in QTcF (Δ QTcF) was 2.6 msec (90% CI: 0.67 to 4.43) for the dose of 120 mg daily (geometric mean Cmax of 1.39 mcg/mL). These results were aligned with the by-time-point analysis showing the mean Δ QTcF between -5.3 msec at Week 9, pre-dose, and 5.7 msec at Week 1, 2 hours post-dose. The 90% 2-sided upper confidence bound for Δ QTcF was below 10 msec at all time points.

UGT2B17 and CYP2C19 Genetic Polymorphism

WELIREG[®] is primarily metabolized by UGT2B17 and CYP2C19. Individuals who are UGT2B17 poor metabolizers are projected to have 2.7-fold higher WELIREG[®] exposures (steady state AUC_{0-24hr}) compared to a UGT2B17 extensive metabolizer and CYP2C19 extensive/intermediate metabolizer. Individuals who are dual UGT2B17 and CYP2C19 poor metabolizers are projected to have 3.3-fold higher WELIREG[®] exposures (steady state AUC_{0-24hr}) compared to a UGT2B17 extensive metabolizer and CYP2C19 extensive/intermediate metabolizer, for the recommended dose. No dose adjustment is recommended, however, close monitoring is recommended. (see [7.1.5 UGT2B17 and CYP2C19 Poor Metabolizers](#) and [10.3 Pharmacokinetics](#)).

Based on publicly available pharmacogenomic databases, Asians had the highest estimated frequency for UGT2B17 poor metabolizers and dual UGT2B17 and CYP2C19 poor metabolizers compared to other racial groups.

Based on publicly available pharmacogenomic databases, the estimated frequencies of CYP2C19 and UGT2B17 poor metabolizers in certain populations are listed below:

UGT2B17 poor metabolizers: 15% of Caucasians, 11% of Latinos, 6% of African Americans, 38% of South Asians, and 69% of East Asians

CYP2C19 poor metabolizers: 2% of Caucasians, 1% of Latinos, 5% of African Americans, 8% of South Asians, and 13% of East Asians

Dual UGT2B17 and CYP2C19 poor metabolizers: 0.4% of Caucasians, 0.1% of Latinos, 0.3% of African Americans, 3% of South Asians, and 9% of East Asians

10.3. Pharmacokinetics

The pharmacokinetics of belzutifan are similar in healthy subjects and patients with solid tumors including advanced RCC. C_{max} and AUC increase proportionally over a dose range of 20 mg to 120 mg.

Table 7 – Population Pharmacokinetic Model Predicted Steady State Parameters in patients

	C_{max} (mcg/mL)	AUC_{0-24hr} (mcg •hr/mL)
Predicted steady state geometric mean (CV%)	1.5 (46%)	20.8(64%)

Absorption

Following oral administration of 120 mg of WELIREG[®], peak plasma concentrations occurred at 1 to 2 hours post dose (median T_{max}).

A high-fat, high-calorie meal delayed time to peak WELIREG® concentration by approximately 2 hours and had no clinically meaningful effect on C_{max} (decrease of 24%) or AUC. Therefore, WELIREG® can be taken without regard to food.

Distribution:

Based on the population PK analysis, the mean (CV%) volume of distribution is 120 L (28.2%). Plasma protein binding of WELIREG® is 45%. The blood-to-plasma concentration ratio of WELIREG® is 0.88.

Metabolism:

WELIREG® is primarily metabolized by UGT2B17 and CYP2C19 and to a lesser extent by CYP3A4. WELIREG® glucuronide conjugate, a major human metabolite does not inhibit HIF-2 α , and has low potential to be a perpetrator of drug interactions. Both UGT2B17 and CYP2C19 display genetic polymorphisms (see [10.3 Pharmacokinetics, Special Populations and Conditions](#)).

Elimination

Based on the population PK analysis, the mean (CV%) clearance is 5.89 L/hr (60.6%) and the mean elimination half-life is approximately 14 hrs.

Excretion

Following oral administration of radiolabeled belzutifan to healthy subjects, approximately 49.6% of the dose was excreted in urine and 51.7% in feces (primarily as inactive metabolites). Approximately 6% of the dose was recovered as parent drug in urine.

Special populations and conditions

Based on population PK modeling, age (19-84 years), sex, ethnicity, body weight (42 kg-166 kg), food, mild (eGFR 60-89 mL/min/1.73 m² estimated by MDRD) to moderate (eGFR 30-59 mL/min/1.73 m²) renal insufficiency, and mild hepatic insufficiency [total bilirubin $\leq$ upper limit of normal (ULN) and aspartate aminotransferase (AST) $>$ ULN or total bilirubin $>$ 1 to 1.5 x ULN and any AST] do not have a clinically meaningful effect on the pharmacokinetics of WELIREG®. Potential differences in exposure across races are possible due to different frequencies of metabolizing enzymes, UGT2B17 and CYP2C19.

- **Sex:** Based on population PK analysis (n=807), female patients (n=278) had 1.6-fold higher WELIREG® exposure (steady state AUC_{0-24hr}) compared to male patients (n=529).
- **Race:** Based on population PK analysis (n=807), Asian patients (n=118) had 2.3-fold higher WELIREG® exposures (steady state AUC_{0-24hr}) compared to Caucasian patients (n=611). This difference in exposure can be due to different frequencies of metabolizing enzymes, UGT2B17 and CYP2C19 (see [8 Adverse Reactions](#)).
- **Pediatrics:** No studies with WELIREG® have been performed in pediatric patients.
- **Geriatrics:** Based on population PK modeling, age (19-84 years), does not have a clinically meaningful effect on the pharmacokinetics of WELIREG®.
- **Renal insufficiency:** Based on a population pharmacokinetic analysis of belzutifan in healthy subjects and patients with cancer, no clinically significant differences in the mean belzutifan

exposure were observed between subjects with normal renal function and those with mild and moderate renal impairment (as evaluated by eGFR). In a dedicated pharmacokinetic study, belzutifan exposure (AUC_{0-12h}) decreased by 6% and increased by 14% in patients with end-stage renal disease before and after hemodialysis, respectively (see [4 Dosage and Administration](#), [7.1.7 Renal insufficiency](#)).

- **Hepatic insufficiency:** Based on a population pharmacokinetic analysis of belzutifan in healthy subjects and patients with cancer, no clinically significant differences in the mean belzutifan exposure were observed between subjects with normal liver function (total bilirubin and AST $\leq$ ULN), and those with mild hepatic impairment (total bilirubin $\leq$ ULN and AST $>$ ULN or total bilirubin > 1 to $1.5 \times$ ULN and any AST). In a dedicated pharmacokinetic study, belzutifan exposure (AUC_{0-12h}) increased by 52% in patients with moderate hepatic impairment (Child-Pugh B). Patients with severe hepatic impairment have not been studied (see [4 Dosage and Administration](#)).
- **UGT2B17 and CYP2C19 Genetic Polymorphism:** WELIREG[®] is primarily metabolized by UGT2B17 and CYP2C19. Poor metabolizers are individuals who are considered to have little to no enzyme activity.

Based on population PK modeling, patients who are CYP2C19, UGT2B17, or dual UGT2B17 and CYP2C19 poor metabolizers, are projected to have 1.3-, 2.7-, or 3.3-fold higher WELIREG[®] exposures (steady state AUC_{0-24h}), respectively, compared to UGT2B17 extensive metabolizers and CYP2C19 extensive/intermediate metabolizers, for the recommended dose. No dose adjustment is recommended based on exposure-response analyses for efficacy and safety.

11. Storage, Stability, and Disposal

Store WELIREG[®] at room temperature, between 15°C to 30°C.

Part 2: Scientific Information

13. Pharmaceutical Information


Drug Substance

Non-proprietary name of the drug substance(s): Belzutifan

Chemical name: 3-[[[(1S,2S,3R)-2,3-Difluoro-2,3-dihydro-1-hydroxy-7-(methylsulfonyl)-1H-inden-4-yl]oxy]-5-fluorobenzonitrile

Molecular formula and molecular mass: C₁₇H₁₂F₃NO₄S; 383.34 Daltons

Structure (for biologics)/Structural formula:



Physicochemical properties: Belzutifan is a white to light brown powder that is soluble in acetonitrile, dimethoxyethane and acetone, sparingly soluble in ethyl acetate, very slightly soluble in isopropanol and toluene, and insoluble in water.

14. Clinical Trials

14.1. Clinical Trials by Indication

Von Hippel-Lindau (VHL) disease-associated renal cell carcinoma (RCC), central nervous system (CNS) hemangioblastomas and pancreatic neuroendocrine tumours (pNETs)

The efficacy of WELIREG[®] was investigated in LITESPARK-004 (NCT03401788), an open-label Phase 2 clinical trial in 61 patients with VHL disease who had at least one measurable solid tumor (as defined by RECIST v1.1) localized to the kidney and who did not require immediate surgery. Enrolled participants included those with other VHL disease-associated tumours such as pancreatic lesions, pancreatic neuroendocrine tumours (pNETs), central nervous system (CNS) hemangioblastomas and retinal hemangioblastomas, based on central independent review committee (IRC). Of the 61 participants, 50 had CNS hemangioblastomas and 22 had pNET. Patients received WELIREG[®] at a dose of 120 mg once daily. Patients were evaluated radiologically approximately 12 weeks after initiation of treatment and every 12 weeks thereafter. Treatment was continued until progression of disease or unacceptable toxicity. The study excluded patients who had any evidence of metastatic disease, either RCC or other VHL disease-associated tumors, an immediate need for surgical intervention for tumor treatment, any major surgical procedure completed within 4 weeks prior to study enrollment, any major cardiovascular event within 6 months prior to study drug administration, or prior systemic treatments

for VHL disease-associated RCC.

The study population characteristics were: median age of 41 years, 3.3% age 65 or over; 52.5% male; 90.2% White; and 82.0% had an ECOG PS of 0 and 16.4% had an ECOG PS of 1. Seventy-seven percent of patients had prior RCC surgical procedures.

The major efficacy endpoint for the treatment of VHL disease-associated RCC was objective response rate (ORR) measured by Integrated Radiology and Oncology Assessment (IRO) assessment using RECIST v1.1 as assessed by IRC. Additional efficacy endpoints included duration of response (DoR) and time to response (TTR). Radiographic endpoints were assessed by IRC using RECIST v1.1.

Table 8 - Summary of trial design and study demographic (LITESPARK-004)

Study #	Study design	Dosage, route of administration	Study subjects (n)	Mean age (Range)	Sex
MK-6482-004 (LITESPARK-004)	Open-label	120 mg, oral	61	41 (19, 66)	Male: 32 (52.5%) Female: 29 (47.5 %)

Table 9 summarizes the efficacy results for VHL disease-associated RCC tumors in LITESPARK-004 after a median follow-up of 37.7 months (range: 4.2, 46.1).

Table 9 – Efficacy Results for WELIREG® for VHL Disease-Associated RCC Tumors (LITESPARK-004)

Primary Endpoints	WELIREG® 120mg daily N= 61
Objective Response Rate * n (%) (95% CI)	39 (63.9%) (50.6%, 75.8%)
Complete response	4 (6.6%)
Partial response	35 (57.4%)
Duration of Response†	
Median in months (range)	Not reached (5.4+, 35.8+)
% (n) with duration ≥ 12 months	35 (100.0%)
Time to response	
Median in months (range)	11.1 (2.7, 30.5)

*Response: Best objective response as confirmed complete response or partial response

† Based on Kaplan-Meier estimates

+ Denotes ongoing response

Results presented in this table reflect a median follow-up of 37.7 months (range: 4.2, 46.1)

Efficacy endpoints for the treatment of other VHL disease-associated tumors included ORR, and response duration, as assessed by IRC using RECIST v1.1. These results are shown in Table 10.

Table 10 - Efficacy Results for WELIREG® for Other VHL Disease-Associated Tumors

	WELIREG® 120 mg daily N=61	
Endpoint	Patients with Evaluable pNET N=22	Patients with Evaluable CNS Hemangioblastomas[‡] N=50
Objective Response Rate* n (%) (95% CI)	20 (90.9%) (70.8%, 98.9%)	22 (44%) (30.0%, 58.7%)
Complete response	7 (31.8%)	4 (8.0%)
Partial response	13 (59.1%)	18 (36.0%)
Duration of Response[‡]		
Median in months (range)	Not reached (11+, 37.3+)	Not reached (3.7+, 38.7+)
% (n) with duration ≥ 12 months	19 (100%)	16 (90%)
Time to response		
Median in months (range)	8.2 (2.5, 16.4)	5.4 (2.3, 33.1)

*Response: Best objective response as confirmed complete response or partial response

‡ Based on Kaplan-Meier estimates

+ Denotes ongoing response

‡ Reflect analysis with tumor measurements that included both solid tumour and associated cystic components if present.

Results presented in this table reflect a median follow-up of 37.7 months (range: 4.2, 46.1)

Renal cell carcinoma (RCC)

The efficacy of belzutifan was evaluated in LITESPARK-005, an open-label, randomized, active-controlled Phase 3 clinical study comparing belzutifan with everolimus in 746 patients with unresectable, locally advanced or metastatic clear cell RCC that has progressed following PD-1/L1 checkpoint inhibitor and VEGF receptor targeted therapies either in sequence or in combination. Patients could have received up to 3 prior treatment regimens and must have measurable disease per RECIST v1.1. Patients were randomized in a 1:1 ratio to receive 120 mg belzutifan or 10 mg everolimus by oral administration once daily. Randomization was stratified by International Metastatic RCC Database Consortium (IMDC) risk categories (favorable versus intermediate versus poor) and number of prior VEGF receptor targeted therapies (1 versus 2-3).

Table 11 - Summary of trial design and study demographic (LITESPARK-005)

Study #	Study design	Dosage, route of administration	Study subjects (n)	Mean age (Range)	Sex
MK-6482-005 (LITESPARK-005)	Open-label	120 mg belzutifan, oral 10 mg everolimus, oral	746	63 (22-90)	Male: 581 (77.9%) Female: 165 (22.1 %)

Patients were evaluated radiologically at Week 9 from the date of randomization, then every 8 weeks through Week 49, and every 12 weeks thereafter.

Among the 746 patients in LITESPARK-005, the baseline characteristics were: median age 63 years [range 22-90 years], 42% age 65 or older; 78% male; 79% White; 12% Asian; 1.1% Black or African American; 43% ECOG performance status 0 and 55% ECOG performance status 1. Prior therapies: 13% of patients had 1 prior line of therapy, 43% had 2 prior lines of therapy and 43% had 3 prior lines of therapy; 49% received 2 to 3 prior VEGF receptor targeted therapies. Patient distribution by IMDC risk categories was 22% favorable, 66% intermediate, and 12% poor.

The primary efficacy outcome measures were Progression-Free Survival (PFS) measured by BICR using RECIST v1.1, and Overall Survival (OS). Secondary efficacy outcome measures included objective response rate (ORR), and duration of response (DOR) by BICR using RECIST v1.1.

The trial demonstrated a statistically significant improvement of PFS for patients randomized to WELIREG[®] compared with everolimus. The efficacy results for advanced RCC in LITESPARK-005 are summarized in Table 12.

Table 12 - Efficacy Results (BICR assessment) for Belzutifan in LITESPARK-005

Efficacy Outcome Measure	Belzutifan n=374	Everolimus n=372
PFS, % (n)*		
Number of events	69% (257)	70% (262)
Progressive disease	63% (234)	60% (222)
Median PFS in months (95% CI) [†]	5.6 (3.9, 7.0)	5.6 (4.8, 5.8)
Hazard ratio‡ (95% CI)	0.75 (0.63, 0.90)	
p-Value	0.00077	
OS, % (n)¥		
Number of events	68% (254)	70% (259)
Median OS in months (95% CI)	21 (18, 24)	18 (16, 22)
Hazard ratio (95% CI)	0.92 (0.77, 1.10)	
p-Value	NS [¶]	
ORR, % (n) (95% CI) §	22% (82) (17.8, 26.5)	3.5% (13) (1.9, 5.9)
Complete response	2.7% (10)	0% (0)
Partial response	19% (72)	3.5% (13)
p-Value	< 0.00001	

* Based on first pre-specified interim analysis for PFS with a median follow-up time of 14 months (range 0.2-31.8).

† From product-limit (Kaplan-Meier) method for censored data

‡ Based on the stratified Cox regression model.

¥ Based on the pre-specified final analysis for OS with median follow up time of 20 months.

¶ Not statistically significant after adjustment for multiplicity.


+ Indicates there is no progressive disease by the time of last disease assessment.

§ Based on Kaplan-Meier estimation.

At a subsequent pre-specified analysis with median follow-up time of 17.8 months (range: 0.2 - 39.1 months) there were 289 PFS events for WELIREG® and 276 PFS events for everolimus. The median PFS was 5.6 months (95% CI: 3.8, 6.5) for WELIREG® versus 5.6 months (95% CI: 4.8, 5.8) for everolimus. The PFS hazard ratio was 0.74 (95% CI: 0.63, 0.88) (Figure 1). The median duration of response was 19.5 (range: 1.9 - 31.6+) for WELIREG®. Based on Kaplan-Meier estimates, patients with a DOR ≥ 12 months was 73% for WELIREG®. At the time of the subsequent pre-specified analysis, 59% of the patients had died in the randomized population (213 patients in the WELIREG® group and 228 in the everolimus group).

The median Time to Response (TTR) was 3.8 months (range: 1.7 - 22.0) in the belzutifan group and 3.7 months (range: 1.8 - 5.4) in the everolimus group. ORR analysis demonstrated ORR of 22.7% for WELIREG® versus 3.5% for everolimus.

Figure 1: Kaplan-Meier Curve for Radiographic Progression-free Survival in LITESPARK-005*



*Based on the second pre-specified interim analysis.

15. Microbiology

No microbiological information is required for this drug product.

16. Non-Clinical Toxicology

General toxicology

The toxicologic potential of belzutifan was assessed via oral treatment in Sprague-Dawley rats and Beagle dogs. Reduction in red blood cell parameters (red blood cell counts, hemoglobin and hematocrit) and reticulocytes were observed in both animal models at exposure levels lower than the human exposure at the recommended dose of 120 mg daily.

In a repeat dose toxicity study where rats were dosed 2, 6, 20 or 200 mg/kg/day for 91 days, belzutifan caused irreversible testicular atrophy/degeneration at ≥ 0.2 times the exposure observed in humans (based on AUC) at the clinical recommended dose of 120 mg daily (see [16 NON-CLINICAL TOXICOLOGY, Reproductive and Developmental Toxicology](#)). An increase in hepatocellular necrosis was also recorded

across all dosing level, however, it was considered incidental. The NOAEL was considered to be 2 mg/kg/day (approximately 0.1 times the human exposure) in males and 200 mg/kg/day (approximately 1 time the human exposure based on AUC) in female rats.

In a 13-week study, dogs received 1, 5, or 30 mg/kg/day of belzutifan. No testicular toxicity was observed at any dose. Decreases in thymus weight that correlated with the microscopic finding of lymphoid hypocellularity in the thymus were noted in females and high dosed males, but were considered incidental. The NOAEL was determined to be 30 mg/kg/day, equivalent to 2 times the exposure (AUC) expected in patients at the 120 mg daily dose.

Genotoxicity

Belzutifan was not mutagenic in the in vitro Ames bacterial cell assay or the in vitro micronucleus assay. Belzutifan was not genotoxic in an in vivo rat bone marrow micronucleus assay.

Carcinogenicity

Carcinogenicity studies have not been conducted with belzutifan.

Reproductive and developmental toxicology

Fertility studies with belzutifan have not been conducted. In repeat-dose toxicity studies up to 3-month duration, WELIREG®-related findings included degeneration/atrophy of male reproductive organs in rats administered ≥ 2 mg/kg/day (approximately 0.1 times the human exposure at the recommended dose of 120 mg daily). Some of these findings were not reversible and were associated with decreased sperm count, motility and abnormal sperm morphology, therefore impairment of male fertility in rats is expected.

There were no findings in female reproductive organs in either rat or dog 3-month studies. However, in an animal embryo-fetal development study, oral administration of WELIREG® to pregnant rats during the period of organogenesis at dose levels of 6, 60, or 200 mg/kg/day (maternal plasma systemic exposures ≥ 0.2 times the human exposure based on area under the curve (AUC) at the recommended dose of 120 mg daily) resulted in embryo-fetal lethality (post-implantation loss), reduced fetal body weights, fetal rib malformations, and reduced skeletal ossification.

Patient Medication Information

READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE

WELIREG® belzutifan tablets

This Patient Medication Information is written for the person who will be taking **WELIREG®**. This may be you or a person you are caring for. Read this information carefully. Keep it as you may need to read it again.

This Patient Medication Information is a summary. It will not tell you everything about this medication. If you have more questions about this medication or want more information about **WELIREG®**, talk to a healthcare professional.

Serious warnings and precautions box

- **WELIREG® can harm your unborn baby.**
- **Your healthcare professional will do a pregnancy test before you start taking WELIREG®.**
- **Use birth control that does not contain hormones while you take this medicine. This is because WELIREG® may cause hormonal birth control to not work. Keep using the birth control for at least 1 week after your last dose.**

See the “Other warnings you should know about: Pregnancy information for Females and Males” section for more information.

What **WELIREG®** is used for:

WELIREG® is used to treat adults with:

- von Hippel-Lindau (VHL) disease who need treatment for, and do not require surgery right away for:
 - kidney cancer that has not spread to other parts of the body; or
 - tumors in the brain and spinal cord called central nervous system hemangioblastomas; or
 - a type of pancreatic cancer called pancreatic neuroendocrine tumors, that has not spread to other parts of the body.
- kidney cancer that has spread (advanced renal cell carcinoma) following treatments that:
 - target the immune system and
 - block cancer blood vessels from growing.

How **WELIREG®** works:

WELIREG® blocks the action of a protein that causes your cancer to grow.

The ingredients in WELIREG® are:

Medicinal ingredient: belzutifan

Non-medicinal ingredients: croscarmellose sodium, colloidal silicon dioxide, FD&C Blue #2 aluminum lake, hypromellose acetate succinate, magnesium stearate, mannitol, microcrystalline cellulose, polyethylene glycol, polyvinyl alcohol, talc and titanium dioxide.

WELIREG® comes in the following dosage form:

Tablets, 40 mg

Do not use WELIREG® if:

- you are allergic to WELIREG® or any of the other ingredients of this medicine or container.

To help avoid side effects and ensure proper use, talk to your healthcare professional before you take WELIREG®. Talk about any health conditions or problems you may have, including if you:

- have breathing or lung problems
- have low levels of oxygen in your blood
- have heart problems / heart disease
- have low levels of red blood cells (anemia)
- have kidney problems
- have liver problems

Other warnings you should know about:

- **Check-ups and testing:** You will have regular visits with your healthcare professional, before, during and at the end of your treatment. They will:
 - Check for **hypoxia (low body oxygen levels)** using a pulse oximeter. WELIREG® may cause low oxygen levels in your body. Your healthcare professional may ask you to monitor your oxygen levels at home as well.
 - Do blood tests to check for **anemia (low red blood cell levels in your blood)**. WELIREG® may cause low red blood cell levels in your blood.

See the “Serious side effects and what to do about them” table, below, for more information on these and other serious side effects.

- **Pregnancy information for Females and Males**

Female Patients

- If you are pregnant, able to get pregnant, or plan to become pregnant, talk to your healthcare professional.
- WELIREG® can harm your unborn baby and cause a miscarriage.
- If you are able to become pregnant:
 - Your healthcare professional will do a pregnancy test before you start taking WELIREG®.
 - Avoid becoming pregnant while taking WELIREG®.

- Use birth control while you take this medicine. Keep using birth control for at least 1 week after your last dose. The birth control methods you use must not contain hormones because WELIREG® may cause these types of birth control to not work. Ask your healthcare professional about birth control methods that may be right for you during this time.
- Tell your healthcare professional right away if you become pregnant or think you may be pregnant during your treatment with WELIREG®.
- If you are breastfeeding or plan to breastfeed, talk to your healthcare professional.
 - It is not known if WELIREG® passes into your breast milk. It may harm your baby.
 - Do not breastfeed while you are taking WELIREG® and for at least 1 week after your last dose.

Male Patients

- Avoid fathering a child while you are taking WELIREG®.
- During your treatment with WELIREG®, use a condom each time you have sex with a woman who is pregnant, may be pregnant or could get pregnant. Continue using condoms for at least 1 week after your last dose.
- If during treatment with WELIREG®, your partner becomes pregnant or thinks she may be pregnant, tell your healthcare professional right away.
- **Fertility**
 - WELIREG® may cause fertility problems in females and males. It is unknown if these problems would be permanent. If you want to have children, talk to your healthcare professional before taking WELIREG®.
- **Driving and using machines:** Before you drive or do tasks that require special attention, wait until you know how you respond to WELIREG®. You may feel dizzy or tired after taking WELIREG®. If this happens, do not drive or use tools or machines until you no longer feel dizzy or tired.
- **Children and Adolescents (less than 18 years of age):** It is not known if WELIREG® is safe and effective for use in people under 18 years old. Do not give this medicine to children and adolescents under 18 years old.

Tell your healthcare professional about all the medicines you take, including any drugs, vitamins, minerals, natural supplements or alternative medicines.

The following may interact with WELIREG®:

- Some medicines may increase the risk of side effects with WELIREG®, like:
 - imatinib (used to treat cancer)
 - fluconazole (used to treat fungal infections)
 - fluoxetine, fluvoxamine (used to treat depressive disorders)
 - ticlopidine (used to prevent stroke)
- WELIREG® may affect the way other medicines work, like:
 - hormonal birth control such as desogestrel, ethinylestradiol and levonorgestrel

- medicines used for sedation and to help sleep such as midazolam

How to take WELIREG®:

- Take WELIREG® exactly as your healthcare professional has told you. Check with your healthcare professional if you are not sure.
- Take WELIREG® with or without food.
- Swallow each tablet whole. Do not break it up.

Usual dose:

- **Adults:** 120 mg (three 40 mg tablets) once per day.
- Your healthcare professional may lower your dose, stop your treatment for a period of time or recommend that you stop treatment completely. This may happen if:
 - you experience serious side effects, or
 - your disease gets worse

Overdose:

If you think you, or a person you are caring for, have taken too much WELIREG®, contact a healthcare professional, hospital emergency department, regional poison control centre or Health Canada's toll-free number, 1-844 POISON-X (1-844-764-7669) immediately, even if there are no signs or symptoms.

Missed dose:

- If you miss a dose of WELIREG®, take the missed dose as soon as possible on the same day. Take your regular dose of WELIREG® the next day.
- If you vomit after taking WELIREG®, do not take another WELIREG® tablet. Take your regular dose of WELIREG® the next day.
- Do not take 2 doses at the same time.

Possible side effects from using WELIREG®:

These are not all the possible side effects you may have when taking WELIREG®. If you experience any side effects not listed here, tell your healthcare professional.

- anxiety
- back pain
- changes in weight, including weight gain
- chest pain
- constipation
- cough
- difficulty sleeping
- dizziness
- feeling like you're going to throw up (nausea)
- feeling tired
- headaches

- muscle pain
- shortness of breath
- stiff joints

WELIREG® can cause abnormal blood test results. Your healthcare professional will do blood tests during your treatment. These will tell your healthcare professional how WELIREG® is affecting your blood.

Serious side effects and what to do about them

Frequency/Side Effect/Symptom	Talk to your healthcare professional		Stop taking this drug and get immediate medical help
	Only if severe	In all cases	
Very common			
Anemia (decreased number of red blood cells): fatigue, loss of energy, irregular heartbeats, pale complexion, shortness of breath, weakness/tiredness, dizziness		X	
Common			
Hypoxia (low oxygen in your body): trouble breathing, shortness of breath, chest pain, dizziness, headaches, weakness of limbs, ringing/buzzing/clicking/hissing in ears		X	
Eye problems: blurred vision, reduced vision, loss of side vision in eye, decreased sharpness of vision, blocked eye veins, increased sensitivity of the eyes to light, eye pain or redness, dark floating shapes and flashes of light in field vision, eye irritation, swelling and itching of the eyelids		X	
Less Common			
Blood clot (blocked artery): weakness, drooping of face, numbness			X
Intracranial hemorrhage (bleeding within the skull): sudden tingling, weakness, numbness in face, arm, or leg			X

If you have a troublesome symptom or side effect that is not listed here or becomes bad enough to interfere with your daily activities, tell your healthcare professional.

Reporting side effects

You can report any suspected side effects associated with the use of health products to Health Canada by:

- Visiting the Web page on Adverse Reaction Reporting (canada.ca/drug-device-reporting) for information on how to report online, by mail or by fax; or
- Calling toll-free at 1-866-234-2345.

NOTE: Contact your healthcare professional if you need information about how to manage your side effects. The Canada Vigilance Program does not provide medical advice.

Storage:

- Store WELIREG® at room temperature (15°C to 30°C).
- Keep out of reach and sight of children.

If you want more information about WELIREG®:

- Talk to your healthcare professional
- Find the full product monograph that is prepared for healthcare professionals and includes the Patient Medication Information by visiting the Health Canada Drug Product Database website (<https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/drug-product-database.html>); the manufacturer's website www.merck.ca; or by calling 1-800-567-2594.

This leaflet was prepared by Merck Canada Inc.

Date of Authorization: 2026-08-05

® Merck Sharp & Dohme LLC. Used under license.

© 2022, 2026 Merck & Co., Inc., Rahway, NJ, USA and its affiliates. All rights reserved.